Here’s a new stock recommendation from Value Research

[Value Research editors]( 22nd December, 2023 --------------------------------------------------------------- Dear {NAME}, Our New Stock Recommendation is out! The Indian pharmaceutical industry is projected to reach a milestone of $130 billion by 2030. You can benefit from this growth with our upcoming stock recommendation! It is a leading player in the pharma space and is growing fast. Its earnings have compounded rapidly over the last three years. With healthy cash reserves, it has sufficient firepower to invest in new therapies, scale up operations and make acquisitions. The business continues to strengthen its domestic sales and is expanding its footprint overseas as well. The last few quarters have gone exceptionally well for it, and it is gaining market share over time. A leader in many of its therapeutic areas, it continues to innovate and contribute to the well-being of people around the world. However, it has come in the crosshairs of the USFDA. The market has overblown the fears of how an import ban will hit the company even as the management has been actively working to reduce the impact of any such possibility. This has led to attractive valuations for an industry leader having a high earnings growth rate. Start your membership to instantly access this fresh stock pick. You’ll also get a selection of over 50 recommendations. Our analysts shortlist 12-15 of our in-house favourites from these recommendations every month to help you get started. [Sign up to learn more about our Stock Advisor and get access to all our recommendations plus new stock ideas as soon as they are released.]( Regards, Dhirendra Kumar Chief Executive Value Research [vro-logo]( Copyright © Value Research India Private Limited 2023. All rights reserved. C-103, Sector 65 Noida, 201301. [Manage Newsletters]( [Unsubscribe]( [Privacy Policy]( Follow us [twitter-icon]( [facebook-icon]( [youtube-icon]( [linkedIn-icon]( [instagram-icon](